Halozyme Therapeutics PEG Ratio

Halozyme Therapeutics's peg ratio stands at 76.34. That is above the Healthcare sector average of 2.56. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Halozyme Therapeutics sits higher the Healthcare benchmark (2.56) with a PEG ratio of 76.34. That is roughly 2882.3% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 76.34 is attractive depends on Halozyme Therapeutics's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Halozyme Therapeutics's PEG ratio evolved across reporting periods, while the comparison chart places HALO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, PEG ratio is commonly used to spot outliers. Halozyme Therapeutics's reading of 76.34 (sector avg 2.56) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.